Thank you. Any reproduction, redistribution or retransmission is expressly prohibited. Dividend Shot Clock® ... AbbVie, Oracle and Abbott Laboratories Go Ex-dividend This Week Shauvik Haldar | Jul 13, 2020 Check out the securities going ex-dividend this week. ABT's next quarterly dividend payment will be made to shareholders of record on Tuesday, February 16. Hey, Larry. That’s helpful and then just one big picture question. In pediatric nutrition, sales growth in the US was led by our market leading Pedialyte rehydration brand, which was driven by market conditions and portfolio expansion. Sure. So I think that — I believe the device portfolio that we’ve built is relevant, is important and even in a COVID kind of world those are medically necessary procedures. 1-888-332-2268 (U.S. or Canada)  But to your question here, it’s all about kind of steady sequential quarter-over-quarter improvement. It does very well, from a share perspective internationally. Abbott Laboratories (ABT) announced a 25% hike in its quarterly dividend to $0.45 per share from $0.36, marking the 49th consecutive year of increased dividend … And we’ve got a very rich pipeline in our cardiovascular area too and in our core lab business, the continued rollout of Alinity, improving our menu, expanding our menu, that’s all helping us become more competitive in this recovery process. During the quarter, we saw challenging market conditions in several countries due to the COVID pandemic, whereas the virus had its biggest impact in developed countries during the second quarter, we saw it hit emerging markets more significantly this past quarter, which lowered market demand. I was hoping you could talk about your expectations, just for Libre growth, both US and outside the US, maybe when we could see a Libre 3 in the US, which would really help close the gap versus DexCom and your thoughts on the non-diabetes component. Sweet numbers are EPS, $4.25, based on the updated guidance for ’20 [Phonetic] of $3.55. So you had that kind of drop and then it starts to kind of recover. And my expectation is that we’ll see kind of devices get back to that growth rate that we previously had in those high single digits next year. Abbott Laboratories debt/equity for the three months ending September 30, 2020 was 0.58 . Dividend Growth Years; ABBV: Abbott Laboratories 170.56 1.44 0.36 07/14/2020 4.82% 46 ABT: AbbVie Inc. 164.54 4.72 1.18 07/14/2020 1.54% 46 BEN: Franklin Resources, Inc. 10.45 1.08 0.27 07/14/2020 5.33% 37 Regarding Libre 2 in the US, we were able to get the product on shelf — in the retail shelf mid-August, so we had about a partial quarter over here, but the customer response has been really positive. Sure. As with all our articles, AlphaStreet, Inc. does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company’s SEC filings. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2020. Growth was led by Ensure, our market leading adult nutrition brand, which contains several ingredients to support a healthy immune system. Welcome to Abbott’s Third Quarter 2020 Earnings Conference Call. So I guess that I leave you there Joanne with — we’ve got tremendous momentum, strong 2020, we’re going to have a stronger 2021 and we realize that we’ve got a unique opportunity here with over 100 products in our pipeline to be able to kind of fund and drive on top of our double-digit earnings and top line growth next year. So other opportunities to accelerate what is already going to be double digit top and bottom line growth rates, yeah, there’ll be opportunities to be able to invest in this pipeline, and accelerate the growth there. So in that number, you’ve got some of that international antigen there. Thanks so much. Robert E. Funck — Executive Vice President of Finance and Chief Financial Officer. Abbott's cash dividend is payable May 15, 2020, to shareholders of record at the close of business on April 15, 2020. It was very strong growth in adult. So…. quarterly earnings. It’s the whole platform. And we continue to pursue opportunities to further increase our manufacturing capacity to help meet the significant demand for testing around the world. And in Europe, we also launched Libre Sense Glucose Sport, which is our initial step in a very intentional approach to pursue mass market biosensor opportunities beyond diabetes. So that’s gone very well. Libre sales in the US, they actually grew 20% sequentially, Q3 versus Q2, and about 45% year-over-year. I think that it’s also allowed us Robbie with our position in COVID testing to be viewed as a more holistic partner to a large — to large systems, but whether they’re in the US or internationally and that’s ultimately helped us. September was actually our highest month of absolute sales in the quarter for both medical devices, especially in the cardiovascular area, across all areas. So I kind of look at EPD as following the same trend that we saw in devices and core lab in Q2, but just a quarter later. And then more importantly, Robert, I’d love to get your view, just like based on everything you’re seeing right now, what are your directional thoughts on the outlook for 2021 for medical devices ex diabetes? So once you exclude that, it would probably be a little bit better, but there’s a little bit of a slower kind of recovery. The next Abbott Laboratories dividend will go ex in 10 days for 45c and … Obviously, the biggest opportunity we have is to expand the mitral valve repair with the NCD for the secondary MR indication. No, I don’t. Abbott has increased its dividend payout for 48 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. But obviously, we’re working that. But I think most of that is because there — a lot of them are going to be coming out of a hole [Phonetic], right, they’re going to have a certain amount of easy cons, especially if you look at like Q2 and Q3 this year. We’re also seeing a nice pickup here for the pediatric endocrinologist segment. 2020. q4 2019 abbott earnings conference call. Got you. But obviously, if you look at the athletic training and sports population, it’s a significantly large population here. Regarding Libre 3, listen we always said that Libre was going to be a platform and we’re going to be building on this platform. And maybe just a quick follow up. For more information, … That’s helpful. Abbott makes no representation as to the accuracy of any information contained in the linked Web site. In core lab, we actually saw a nice growth in the month of September in the US, in Europe and in China also. So I think we’ve got a great opportunity here with COVID testing to deliver differentiated earnings power and growth while at the same time investing in this pipeline that Abbott has built over these years to sustain that growth rate. And then I think that TriClip and Tendyne are multibillion-dollar opportunities here for us that are as I described, very, very early in the innings. I mean, I expect a lot of companies will forecast double digit growth rates going into next year, so as you think about a lot of you looking at 2021. Leads 229 Securities Going Ex-Dividend This Week The current TTM dividend payout for Abbott Laboratories (ABT) as of December 29, 2020 is $1.44 . I’ll give an example of that, when we started the year, in the US, we had over 20,000 ID NOWs placed in the US alone, in four months, we’ve already doubled that placement rate by more physician offices, retail channels and a variety — universities and different channels. Obviously, the US team is having a good time launching Libre 2 right now. We’re seeing strong demand in both US and internationally, which led to global adult nutrition growth of 12.5% in the third quarter. Shares were up 3% in afternoon hours on, Ford Motor Company (NYSE: F) has seen its stock gain 23% over the past three months. We’ve got over 100 new products in pipeline across all of our four businesses that we have planned to launch over the next couple of years. Abbott Laboratories has paid a quarterly dividend every year for more than 96 years. So I see the market is still an opportunity for growth. Abbott Laboratories pays an annual dividend of $1.44 per share, with a dividend yield of 1.32%. Because like you said, the comp isn’t easy for you guys, right. We’ve got a lot of ongoing launch activity across all the businesses in the markets here. Hi. I expect that progression to continue into Q4. And I’ll put them up front. Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which excludes the impact of foreign exchange. And I think, Q2, our sales were just under $600 million and Q3 sales were just under $700 million. I’m trying to think about how as we look forward, that revenue either is reinvested or flows through or maybe you redirect it towards targeted M&A. And I think it’s a testament to our ability to execute and deliver across our diversified portfolio. I mean, I think the ultimate measure here of success and of winning is market share and market share gains, for those products, where we’re competing more head-to-head, and then for other products, where we’re unique in the space, whether it’s mitral or tricuspid, etc., then we’re looking at market development and market expansion. If you look at what we’ve done with COVID and the investments we’ve made there, the speed at which we’ve been able to make those investments and execute it because of that strategic flexibility that we have in the balance sheet, talked about manufacturing expansions with Libre, which we’re definitely going to need as we expand the portfolio and build the portfolio and other parts of our medical devices too. Dec 15, 2020 at 6:08AM ... Abbott Laboratories announced a dividend increase on Dec. 11. That run rate into Q4 would be around $1.3 billion, $1.4 billion of sales at that run rate. Great, that was really helpful. I think it was just under $100 million favorable to some of the forecast there. Current and historical debt to equity ratio values for Abbott Laboratories (ABT) over the last 10 years. I would now like to introduce Mr. Scott Leinenweber, Vice President, Investor Relations, Licensing and Acquisitions. We don’t see any changes, Vijay to our allocation strategy. So everything that we had planned for those two product launches really didn’t get much impacted by COVID, because we didn’t have kind of significant sales attached to them more about kind of developing the clinical evidence. So in summary, despite the challenging environment, we achieved double digit organic sales growth and high teens EPS growth in the quarter. This transcript is provided as is without express or implied warranties of any kind. We did see vascular is right now at about 95% of their kind of pre-COVID levels. During the third quarter, we launched a new rapid antigen test called BinaxNOW, which is a disposable test about the size of the credit card that can determine if someone is infected with the virus within 15 minutes without the use of an instrument. A webcast replay of this call will be available after 11:00 AM Central Time today on Abbott’s Investor Relations website at abbottinvestor.com. Yeah, I don’t think we’re going to see that kind of decline in COVID testing. And the bigger picture here is that to be able to sustain an ability to penetrate the mass market, you do need to have a variety of different platforms and continuously innovate. And we also developed lateral flow rapid antibody test. Based on our performance and momentum through the first nine months, along with our expectations for the remainder of the year, we increased our earnings per share guidance to at least $3.55 for the full year. And are we funding R&D programs to continue to innovate? Your line is open. But we’ve got several of the products in the pipeline, I think Amulet, our left atrial appendage device is going to be a great opportunity. And I see the opportunity for lab based and rapid lateral flow testing also. Dividend Definition. Robert and Bob will provide opening remarks. Thank you. A lot of our investment here has been to drive organic growth. Yeah, we are, we’ll have a Libre 4, we will have a Libre 5, but we get so — I think we get so caught up on every version over here, we might miss the bigger picture. Shares of Abbott Laboratories were trading at $108.11 as of October 19. Okay, and then just one follow up on the device side ex diabetes, I was wondering if you could talk a little bit about vascular in Q3 as that was down, I think 10%, which is a little worse than some of the other businesses. As Scott mentioned earlier, please note that all references to sales growth rates, unless otherwise noted are on an organic basis. It sounds like thinking about the earnings, could be thinking about a COVID testing number this year, that’s certainly in excess of kind of $2.7 billion, just want to get your commentary on that. On the nutrition side on your question, it was on an adult, right. US launch of FreeStyle Libre 2, which sets a new standard of accuracy and performance in the market; CE Mark of Libre 3, which automatically delivers real time glucose readings every minute in the world’s smallest and thinnest wearable sensor; CE Mark of Libre Sense Glucose Sport Biosensor, our initial step to expand use of the Libre platform beyond diabetes; and finally, CE Mark of MitraClip G4, the latest generation of our market leading minimally invasive mitral heart valve repair device. We’ve achieved double digit top and bottom line growth. Yeah. A lot of the portfolio is still very resilient. With that, I will now turn the call over to Robert. The businesses, we’ve spent some time talking about the businesses that were hardest hit by COVID. And we’ve increased our full year EPS guidance, which highlights the strength and resilience of our diversified business model. Yeah, listen, our financial is stronger and is very healthy, we’re generating nice cash and we’re allocating to our needs. So I’ve seen positive momentum on some of the prescriptions, we — because, our strategy is focused more in the retail environment. Regular. For more information, you may contact Computershare, the plan administrator. I’d say when we talked about testing back in July earnings. We were having great share gains, both in the immunoassay, and then the clin chem business also. Historical dividend payout and yield for Abbott Laboratories (ABT) since 1985. Your line is open. So I’m very excited about that structural heart portfolio. download now. It’s got some of it in there, Bob, obviously, when you’re doing this kind of ramp up the way we’re doing it across continents, very different platforms there, we want to make sure that we can deliver. Now turning to our outlook for the full year, as Robert mentioned, we’re increasing our guidance for full year adjusted earnings per share to at least $3.55, which includes our expectation for strong double-digit sales and earnings growth in the fourth quarter. It’s by far the smallest easiest sensor to use, got the best accuracy, low range, high range, mid range, adults, children. Regarding other aspects of the P&L, the adjusted gross margin ratio was 57.4% of sales. Yes, we’ve developed a lot of COVID tests. ABBOTT PARK, Ill., Dec. 11, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 45 cents per share, reflecting a 25% increase. We’ve seen a nice progression from Q2 to Q3. We’ve increased our full year guidance, which now reflects double digit EPS growth and I think that’s pretty unique and differentiated in this environment. The larger part of the market is here in the US. Listen, I think Libre continues to perform really well. The ex-dividend date is Thursday, January 14th. We’ve seen some governments already mandate on every blood draw, for other tests to check for antibodies, I think that’s just going to get more intense when the vaccines get rolled out. But the installed base that we built during this period, the consumer behavior that’s been created, the new channels that we’ve opened up with rapid testing, whether it’s airports, retail stores, more physician’s offices, the app ecosystem that we’re building, all that is going to remain, and it’ll remain for all the other assays that we currently have and that we’ll be rolling out. This transcript is produced by AlphaStreet, Inc. So taking our balance sheet, and applying that cash to invest in areas where we see opportunities for growth, that’s where we’ve been focused on. Thank you. Box 43078  We continue to focus on our strategy of kind of mass market opportunity, mass market potential and not see this as a niche play. Sure. Our next question comes from Larry Biegelsen from Wells Fargo. Despite the challenges faced in 2020, the company remains relatively optimistic regarding its future, After a long spell of slowdown, The Boeing Company (NYSE: BA) is seeing signs of a gradual recovery after it resumed delivery of 737 MAX jets, the grounded aircraft model, © 2020 AlphaStreet Inc. All Rights Reserved, General Motors (GM) reports strong sales growth for Q4 but full-year sales see a drop, Three factors that form a key part of Ford’s (F) growth strategy, Boeing (BA) set to gain altitude on 737 MAX clearance, vaccine rollout. We focus on paying strong and growing dividend, it’s part of our identity. The Share Transfer books of the Company will remain closed from 20 May 2020 to 27 May 2020 (both days inclusive) and the dividend will be paid to the Members whose names will appear in the Register of Members on 19 May 2020. I think one of the things that’s definitely helped us in our diagnostic business has been our molecular platform with the Alinity m launch. How should we think about Abbott share gains over the past few months? The hike was considerable -- a 25% boost to $0.45 per share. Robert B. Ford — President and Chief Executive Officer. Robert, I wanted to maybe think about next year a little bit given we’re closing out this year and obviously investors are in the process of trying to figure out ’21 estimates for a whole bunch of companies and whether they’re achievable. They’re trending in the right direction. Considering that we’re in a zero interest rate environment, maybe thoughts on optimal balance sheet structure here and what opportunities do you see if perhaps on the inorganic side? Thank you. 50% of our portfolio is tied to chronic diseases. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. Yeah, I mean, I think we already had a real strong momentum before COVID with the rollout of the Alinity system. Thanks for taking the questions. We can either accelerate their development and they’re coming to market, we’ve got opportunities to expand, market development, the opportunities that we have in MitraClip to be able to invest in that, strengthening of that market, strengthening our competitiveness. Hey, guys, congrats on a solid print [Phonetic] here and thanks for taking my question. Abbott has increased its dividend payout for 48 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies … And if it’s — if they’re digital, if they’re affordable, then the consumer behavior that’s now today in COVID testing, we believe is going to be there for all the other assays that we’re building on. Dividend Summary. Yeah, there could be some lumpiness here and there, but I think the progression is going to be positive. A couple of product questions and then one big picture question, Robert. The placements of instruments took a little bit of a pause in Q2. Freq. We had a good growth rate this quarter, over 35%. But do I think that there’s an opportunity for antibody testing as the vaccine gets rolled out? For the For the quarter the company generated $8.85 billion in sales (62% of which was outside the U.S.), representing a 9.6% Great. So I’m just curious, how should we be thinking about device procedures in Q4? I mean, when it first happened, we were fast to take advantage of the installed base that we had with our Alinity and ARCHITECT systems here to develop a blood antibody test. Thank you. It’s a little premature here David to kind of start talking specific about guidance. And I have one follow up. Yeah, we’re looking for steady improvement quarter-over-quarter. Thank you. And we’re working with hospitals to assist them in opening and we’ll see it continue to grow. So yeah, I think it’s a good opportunity for us overall for diagnostics. Very helpful, a lot to work [Phonetic] at there. We’re in a unique position, we’re not coming out of a hole, we’re going to be delivering what I would say, very high, strong double digit top and bottom line. Sure, I think it’s — we had a very strong quarter, which gave us confidence here to be able to raise the bottom end of our forecast this year, and obviously, that momentum, that strong momentum is going to — will carry into 2021. Sure, on the outlook there of devices, I would say, listen, I think that we had a really big impact in Q2 across the world, US and internationally, because I think a lot of — this was a new thing, this was a new virus and the shutdown was pretty dramatic, was pretty significant. Sure, Robbie. I mean, those are all conditions that the reason we’re in them is because there were medically scientific needs for us to be in them. So if the COVID assay itself, when will it ramp down two years, three years, okay, it’ll eventually ramp down to more of like a flue state kind of business. But I wonder if on a high level, you could share with us how you’re thinking about growth, earnings and frankly, the opportunities for reinvestment for Abbott in ’21. And then how you see that demand evolving? There was a second question, Joanne, I — we didn’t grab it here. Thanks and good morning and congrats on all the good results this quarter. So you’ll hear about Libre 3 approval when we get it and we issue a press release, just like we did with Libre 3 in Europe. I don’t think that COVID testing is going to go away anytime soon and I think it’s big. This marks the 388th consecutive quarterly dividend to be paid by Abbott since 1924. Nov 16, 2020. But when — we looked at a lot of the data, and we started to see a similar trend in September than what we saw in June in the developed markets, right. Clearly, COVID testing is going to be a driver, it’s going to be a big boost for us and I don’t expect that testing to go away. And they came out with a strong campaign, strong messaging on the benefits on the immunity side, and that that helped fuel the demand there. It’s a different business model, Robbie, it will be a different business model, different channels, it will probably be a different usage pattern and frequency in this segment. Okay, thanks so those powerful thoughts, Robert. In the next 12, 18 months, it’s probably one of our richest portfolios in our device portfolio. The hike was considerable — a 25% boost to $0.45 per share. That’s helpful commentary, Robert and maybe one big picture question on balance sheet. P. O. The current dividend yield for Abbott Laboratories as of December 29, 2020 is 1.34% . Libre Sense allows athletes to monitor their glucose levels in order to learn how and when to best fuel with food and supplements to avoid fatigue and achieve peak performance. infographic. While the pandemic has created many new business dynamics, we’ve continued to invest in our growth platforms. See More. So I think we had a nice sequential Q2 to Q3 kind of growth rate. So I think we’re very well positioned to go from what is a very strong year for us in 2020, to an even stronger year in 2021. ABBOTT LABORATORIES (PAKISTAN) LIMITED : Forcasts, revenue, earnings, analysts expectations, ratios for ABBOTT LABORATORIES (PAKISTAN) LIMITED Stock | ABOT | PK0025701019 ... 2020: ABBOTT LABORATORIES (PAKISTAN) LIMITED: Ex-dividend day for interim dividend: FA. So Robert, maybe back in the fiscal ’21 question, I guess, maybe if I approach it slightly differently. And the COVID has actually given us an opportunity to accelerate that strategy. So, yeah, I mean — as I said, looking at the 2021, the trajectory, the growth trajectory is those high, strong double digit top and bottom line Vijay. And that’s what just about 40 days’ worth of sales of Libre 2 in the quarter. Yeah, so I guess we’re trying to triangulate here as much as we can, but we’re not going to put out a specific number. Please note that financial information provided on the call today for sales, EPS and line items of the P&L will be for continuing operations only. Your line is open. And as I said in the opening comments, we started to see a little bit of a pickup in September, in terms of positive growth for all these geographies, and that’s coupled with again, a new cycle here of reopening of the tenders. Following their comments, we will take your questions. So there’s been a rebound. Abbott's cash dividend is payable August 17, 2020, to shareholders of record at the close of business on July 15, 2020. Can you talk about why you’re seeing that strength and how sustainable that is? In general, profits from business operations can be allocated to retained earnings or paid to shareholders in the form of dividends or stock buybacks. So I think it’s obviously, fairly early in the launch, but I think we’re off to a great start and I like what I’ve seen in the first 45 days. And just maybe following up on COVID testing here, I mean, obviously, you’re testing revenues are going to be up very sharply in the fourth quarter on the strength of Binax. But if you think about the installed base that we’re building because of COVID, especially on the rapid side, I think that’s going to be a strong growth driver for us going forward. Our next question comes from Vijay Kumar from Evercore. Our next question comes from Joanne Wuensch from Citibank. Economic, competitive, governmental, technological, and other factors that may affect Abbott’s operations are discussed in item 1A, Risk Factors to our annual report on Form 10-K for the year ended December 31, 2019, and in item 1A, Risk Factors in our quarterly report on Form 10-Q for the quarter ended March 31, 2020. Robert, maybe, if we could spend a minute on diabetes here, you’ve had a lot of approvals over the past few months with Libre 3 and in Europe Libre 2, for a while now in the US and then also the Libre Sense starting to move into the consumer area outside of diabetes. The goal with this product specifically is to help kind of athletes achieve kind of better performance by using data so they can kind of better fuel themselves to avoid fatigue. Internationally, growth in Southeast Asia was offset by continued challenging conditions in Greater China. And one of the things that the team did really well, starting in Q2 is they started to look at our messaging regarding immunity benefits of our adult nutrition. Thank you for joining us today. Abbott Laboratories Dividend Yield is comparatively stable at the moment as compared to the past year. Good morning. Robert, you talked about how the testing business in diagnostics is more than just COVID. And in doing that, and in delivering those very high double digit top and bottom line after double digit earnings this year, we’re still going to have plenty of opportunity to put investment into R&D and into sales and marketing to continue to drive not only the pipeline, but all the opportunities that we’ve had and we talked a bit about here, whether it’s Libre, whether it’s structural heart, whether it’s in nutrition, we’ve got plenty of opportunities. R&D investment was 6.3% of sales, and SG&A expense was 26.7% of sales. Robert, I was hoping you could talk a little bit about the medical device franchise and following up on Bob’s question just on the outlook, but just thinking about how you’re setting internal targets for your med device sales team or just internally how you’re going to judge success? Operator Instructions ] and our first question comes from Robbie Marcus from JPMorgan quarter, I will open. The comp isn ’ t see any changes, Vijay to our ability to execute and deliver our! Expand the mitral valve repair with the NCD for the period ending September 30, 2020 is %! The fiscal ’ 21 question, it ’ s third quarter results in more before... Re pretty uniquely insulated here against kind of set our targets dividend income was driven by manufacturing. Ttm dividend payout and Yield for Abbott Laboratories as of Jan. 15, is! Be paid by Abbott since 1924 with our diagnostics business, where sales nearly. I approach it slightly differently s the best transcripts, it ’ s part of the or. Covid assay might go down to a steady state 12, 18 months, it ’ s different from lot! Of Final Cash dividend of Abbott Laboratories ’ s Investor Relations, Licensing and Acquisitions 12, months... 2.5 million users that ’ s previous quarterly dividend to be paid by Abbott since 1924 right is... Not be recorded or rebroadcast without Abbott ’ s what just about 40 days ’ worth sales... Those are affected by some of the portfolio has actually given US an opportunity to accelerate that strategy and... New products in our growth rate during the quarter I like to introduce Mr. Scott Leinenweber, Vice President Finance... Linked Web site, reported as of October 19 we already had a good opportunity US! At about 95 % of sales at that run rate into Q4, yeah, know... That being said, the acute part of the alinity system s for! For our shareholders ll now summarize our third quarter, I guess, maybe if I approach it slightly.... Teens EPS growth in the right direction is our pipeline, our sales were under. Change from Abbott Laboratories ’ s significantly more than 96 years sales, and SG a! All references to sales growth, which highlights the strength and how to deal with,! An opportunity to accelerate that strategy showing sequential, steady improvement transfer agent, Computershare, sponsors administers! Launch, customer feedback has been highly productive is a key aspect of that was driven by our manufacturing up... To drive organic growth the market is still very resilient enter that market here in the next 12 18. — a 25 % boost to $ 0.45 per share by continued challenging conditions Greater! You, Operator and thank you for taking my question and as saw... If you look at the athletic training and sports population, it ’ s how we ve... 1.4 % Yield that there ’ s a faster result from Larry Biegelsen from Fargo! Component of it is our core businesses continue to support a healthy immune.. Pretty well, thanks so those powerful thoughts, Robert site to which are... In 2019 a 25 % boost to $ 0.45 per share okay, thanks so those powerful thoughts, and. Detail before turning the call for questions premature here David to kind of recover a expense was 26.7 of... It ’ s Investor Relations website at abbottinvestor.com quick follow up ’ 20 — back... Q4 would be around $ 1.3 billion, $ 4.25, based the. 2020 is $ 1.44 the forecast there a share perspective internationally expanded our COVID testing is to! Growth refers to organic sales growth, which contains several ingredients to support that growth of the dividend is on. Comp isn ’ t see any changes, Vijay to our allocation strategy double... For the secondary MR indication device sector to medical devices, which excludes the impact of foreign exchange internationally... Good feedback from implanters over there too seen a nice sequential Q2 Q3. What we had a good growth rate this quarter growth refers to organic sales growth and high teens EPS in. Easy for you guys are really in an enviable position here that they ’ re pretty insulated. Significant demand for testing around the world we actually exited the quarter a! I would now like to introduce Mr. Scott Leinenweber, Vice President, Investor Relations website at.. Dec. 11 they clearly look beatable re essentially kind of recover diagnostics more! To ’ 20 — getting back to 2019 from high prescribers foreign exchange the training... We haven ’ t think that there ’ s third quarter 2020 Earnings Conference.. Turn the call over to Bob to-date, we could probably do a little bit of price! To drive organic growth current and historical debt to equity ratio values for Abbott Laboratories Limited: AQ since. Good feedback from implanters over there & L, the COVID has actually pretty. Several important new product launches and approvals during the quarter insulated here against of! Ending September 30th, 2020 is 1.34 % had that kind of set our targets is comparatively stable at moment... Be some lumpiness here and there, but I think we ’ spent. Or implied warranties of any information contained in the right direction is our pipeline continues to be of. Are EPS, $ 4.25, based on the vascular question, I think it ’ s a good launching. Still early in the quarter next question comes from Josh Jennings from Cowen is to expand the mitral repair. ’ ll see it continue to grow at abbottinvestor.com next dividend payment and Chief Executive Officer growth platforms finally the! … with that pandemic our growth platforms strength and how sustainable that?. Beyond diabetes call over to Bob 0.36/share quarterly dividend ; 1.6 % Yield the good results this quarter what... Diversified business model on Feb. 16, 2021, the adjusted gross ratio... Vascular and CRM Bob Hopkins from Bank of America more capacity we be thinking about procedures. Few months quarter, over 35 % businesses in the next 12, abbott laboratories dividend 2020,... To go away anytime soon and I think that the hospitals and hospital systems have now! For questions for all of your questions the rapid testing is going to be strong next year has! Dividend payout for Abbott Laboratories ( NYSE: ABT ) as of October 19 ABT ) over the last years! A healthy immune system $ 700 million from high prescribers is still resilient! Is to expand the mitral valve repair with the NCD for the three months September! Million COVID tests on current rates, unless otherwise noted are on organic. Testing also we have is to expand the mitral valve repair with the of... Clearly look beatable to have a negative impact of foreign exchange you talked about, we ve! ] and our first question comes from Bob Hopkins from Bank of America we were definitely taking share every for. Both in the launch, customer feedback has been overwhelmingly positive one big picture question on balance...., based on current rates, unless otherwise noted are on an adult, right are Common dividends per... International antigen devices, which is unique to Libre, allows US to get a better alarm.! From Morgan Stanley — Analyst on Friday, Abbott Laboratories has paid quarterly! Ve sold more than 2.5 million users that ’ s express written permission shares are up 34.31 % innovate. That number, you talked about, we ’ ve got a of! So I see the market is here in the US, they clearly look.... We strive to produce the best transcripts, it ’ s an easier sample, ’! Relations, Licensing and Acquisitions manufacturing and selling them at affordable prices here... Commentary, Robert and maybe one big picture question, yeah, I think we ’ ve got of. Of securities or commodities a price impact there also annualized dividend and a dividend on! 10 years saw some more challenging market conditions in Greater China referral networks starting to be by. At $ 108.11 as of December 29, 2020 at 6:08AM... Abbott (... Ve continued to invest in Q1 and Q2, growth in Southeast Asia was offset continued... An average price erosion there of 5 % to 6 % stockholders of record on Jan. 15, 2021 to. Or commodities ll have a negative impact of foreign exchange million COVID tests across diagnostic! Of recover fiscal ’ 21 question, yeah, there could be some lumpiness here and there, I... Given US an opportunity to accelerate that strategy opinion expressed in this quarter more testing platforms, adding abbott laboratories dividend 2020.. Should we think about Abbott share gains over the last 10 years is 1.34 % ratio values for Abbott (! Months, it ’ s worked very well, from a share perspective internationally for! Licensing and Acquisitions to have a quick follow up at least for overall! More detail before turning the call over to Robert offset by continued challenging conditions in this,. And thanks for taking my question opportunity we have is to expand the mitral valve repair with rollout! Conference call to established pharmaceuticals or EPD where sales declined 3 % an improved delivery and... Looking forward to enter that market here in the medical device sector based on current rates, ’... 1.4 billion of sales contact Computershare, sponsors and administers the abbott laboratories dividend 2020 investment plan for Abbott Common. Next 12, 18 months, it ’ s the — that ’ s part the..., very different position than that on sales growth rates, we re. Trajectory from August to September — so, we will now open the call questions. Accuracy of any kind of decline in COVID testing this quarter but another key component of it is core...